Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
11. Juni 2024 02:00 ET
|
Essential Pharma
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
21. Mai 2024 08:00 ET
|
Bionano Genomics
Optical genome mapping was used in three publications to successfully assess genome integrity in stem cells, CAR-T cells, and iPSCs.
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
09. April 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
01. August 2023 07:00 ET
|
Renaissance Pharma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
01. August 2023 03:00 ET
|
Renaissance Pharma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Pr
20. April 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C...
Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain
16. November 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain DelveInsight’s...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
30. November 2020 07:00 ET
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
13. November 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
09. November 2019 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...